It’s almost the end of 2025, and what a year it has been for us here at Reliant. From our inception, we’ve known that the future of life sciences lies in the intelligent intersection of human expertise and machine learning. Yesterday, we were thrilled to share a major step toward that reality (you can read the official press release here).

We have officially entered into an engagement with Medicus Pharma Ltd.(Nasdaq: MDCX) to develop an artificial intelligence-driven clinical data analytics platform. This isn’t just another tech announcement. It’s a pivotal moment where our generative AI meets real-world clinical stakes to potentially change how life-saving treatments reach patients.

For us as founders, this collaboration hits home. It validates exactly why we started Reliant—to eliminate the "mental menial labor" of data analysis so that brilliant researchers can focus on the science.

‍

The Bottleneck in Clinical Development

If you work in biotech, you know the drill. You have incredible assets in the pipeline. You have smart teams. But you also have friction.

Clinical trials are notoriously complex. They are expensive, time-consuming, and fraught with logistical hurdles. Finding the right sites to run a trial? That is often a guessing game. Finding the right patients who fit specific stratification criteria? That can feel like finding a needle in a haystack of unstructured data.

We have seen too many promising therapeutics get bogged down not because the science was bad, but because the operational execution was inefficient. Data is everywhere, but it is often trapped in silos or buried in literature that no human team has time to fully review.

This is where we come in.

‍

A Shared Vision for Smarter Science

Medicus Pharma Ltd.(Nasdaq: MDCX) is doing incredible work advancing Teverelix, a next-generation GnRH antagonist. They are targeting acute urinary retention and prostate cancer—conditions that affect millions. It’s a $6 billion market opportunity, and an opportunity to substantially improve patient outcomes.

When Medicus Pharma Ltd.(Nasdaq: MDCX) approached us, it was clear they weren’t just looking for a software vendor. They wanted a partner to help them build a "decision-intelligence" engine. They needed a way to cut through the noise and make evidence-based decisions faster.

Our collaboration is designed to build a platform that automates the heavy lifting. We are looking at:

• Dynamic Site Selection: No more static lists. We want to help select trial sites based on real-time data and predictive modeling.
• Patient Stratification: Using AI to identify the specific patient subgroups that will benefit most from the treatment.
• Enrollment Forecasting: Predicting bottlenecks before they happen so the trial stays on track.

‍

Why Generative AI Changes the Game

You might be thinking, "hasn't big data been around for a while?" Sure. But generative AI is different.

Traditional data analytics can tell you what happened in the past. Generative AI, when built correctly, allows for a rich dialogue with the data. It allows you to ask complex questions and get synthesized, fact-checked answers.

At Reliant, we pride ourselves on building AI that is trustworthy. In our view, an AI model that hallucinates is useless in a regulated industry like life sciences. That is why our technology is grounded in "ground-truth" verification. Our system acts like an artificial annotator, checking its own work with human-level accuracy.

For the Medicus Pharma Ltd.(Nasdaq: MDCX) collaboration, this means the platform won’t just spit out numbers. It is intended to synthesize data into a coherent narrative. It empowers the team to look at the same data with a level of clarity that simply wasn’t possible before.

‍

Trust Is Everything

We know that in this industry, trust is the currency we all trade in. You need to trust your data. You need to trust your partners. And increasingly, you need to trust your AI.

We feel deeply honored that Medicus Pharma Ltd.(Nasdaq: MDCX) has chosen us for this journey. It is a testament to the hard work our team—hailing from places like DeepMind, Google Brain, and top life sciences organizations—has put into building a robust, reliable engine.

This engagement is structured to keep us all accountable. It’s a milestone-based approach. We have to deliver real value at every step. We love that pressure. It keeps us sharp and ensures that we remain aligned with our customers’ strategic goals.

‍

Looking Ahead

As we head into the new year, we are filled with optimism. The convergence of biology and computer science is accelerating. We are moving from a world where data analysis was a bottleneck to a world where it is a superpower.

This collaboration with Medicus Pharma Ltd.(Nasdaq: MDCX) is a perfect example of what 2026 is going to look like: agile biotech companies leveraging state-of-the-art AI to punch above their weight and deliver therapies faster.

We are ready to get to work. We are ready to turn data points into stories and insights into action.

If you are at the JP Morgan Healthcare Conference in San Francisco this January, don’t be shy – come say hi. We would love to chat about how we can help you streamline your research and innovate fearlessly.

Here’s to a smarter, faster future for clinical trials.